Allergen-specific immunotherapy: Towards combination vaccines for allergic and infectious diseases

Current Topics in Microbiology and Immunology

Volumn 352, Issue 1, 2011, Pages 121-140

  Edlmayr, Johanna ^a   Niespodziana, Katarzyna ^a   Focke Tejkl, Margarete ^b   Linhart, Birgit ^a   Valenta, Rudolf ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALLERGEN DERIVED PEPTIDE; BIRCH POLLEN ALLERGEN; CARRIER PROTEIN; CPG AMB A 1 CONJUGATE; DER P 1; DNA VACCINE; DOL M V; EPITOPE; HYBRID PROTEIN; HYPOALLERGENIC ALLERGEN DERIVATIVES; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE VACCINE; PROTEIN VP1; RECOMBINANT BET V1 ALLERGEN; RECOMBINANT DNA; RECOMBINANT HYBRID MOLECULE; RECOMBINANT WILDTYPE ALLERGEN; RSBSC BET V 1 CONJUGATE; T CELL EPITOPE PEPTIDE; UNCLASSIFIED DRUG; ALLERGEN CONJUGATE; BACTERIAL PROTEIN; BET V 1 ALLERGEN; HYPOALLERGENIC ALLERGEN DERIVATIVE; IMMUNOGLOBULIN G; RECOMBINANT ALLERGEN; VIRUS PROTEIN;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGENICITY; ALLERGIC DISEASE; ALLERGIC REACTION; ARTICLE; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION; PRIORITY JOURNAL; RHINOVIRUS INFECTION; SENSITIZATION; T LYMPHOCYTE; VACCINATION; ALLERGY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BASOPHIL; CELL ACTIVATION; DESENSITIZATION; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; EXPOSURE; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MAST CELL; PROPHYLAXIS; VACCINE PRODUCTION;

DESENSITIZATION, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; HYPERSENSITIVITY; RECOMBINANT PROTEINS; VACCINES, COMBINED; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRUS DISEASES;

EID: 80053485690     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_130     Document Type: Article

References (106)

1. Akdis CA, Blesken T, Akdis M, Wünthrich B, Blaser K (1998) Role of interleukin 10 in specific immunotherapy. J Clin Invest 102:98-106 (Pubitemid 28323835)
2. Ali FR, Larche M (2005) Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev Vaccines 4:881-889 (Pubitemid 43040908)
3. Bischoff SC (2007) Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 7:93-104 (Pubitemid 46174857)
4. Blackley CH (1873) Experimental researches on the causes and nature of catarrhus aestivus (hay-fever or hay-asthma). Baillière, Tindall & Cox, London
5. Bohle B, Breitwieser A, Zwolfer B, Jahn-Schmid B, Sara M, Sleytr UB, Ebner C (2004) A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol 172:6642-6648 (Pubitemid 38669099)
6. Bostock J (1819) Case of periodical affections of the eyes and chest. Med Chir Trans 10:161
7. Bousquet J, Bousquet PJ, Godard P, Daures JP (2005) The public health implications of asthma. Bull World Health Organ 83:548-554 (Pubitemid 41003331)
8. Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H, Scheiner O, Breitenbach M (1989) The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. Embo J 8:1935-1938 (Pubitemid 19273517)
9. Brunetto B, Tinghino R, Braschi MC, Antonicelli L, Pini C, Lacovacci P (2010) Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy 65:184-190
10. Campana R, Mothes N, Rauter I, Vrtala S, Reininger R, Focke-Tejkl M, Lupinek C, Balic N, Spitzauer S, Valenta R (2008) Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 121:528-530
11. Caulfield AHW (1922) Desensitization of hay fever patients by injection and local application. J Am Med Assoc 79:125
12. Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM, Turner KJ (1988) Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J Exp Med 167:175-182 (Pubitemid 18093701)
13. Cooke RA (1932) Infective asthma: indication of its allergic nature. Am J Med Sci 183:309
14. Cooke RA, Barnard SH, Hrbald AT, Stull A (1935) Serological evidence of immunity with co-existing sensitisation in a type-of human allergy, hay fever. J Exp Med 62:733-750
15. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D (2006) Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355:1445-1455 (Pubitemid 44511559)
16. Curin M, Reininger R, Swoboda I, Focke M, Valenta R, Spitzauer S (2010) Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol 154:258-263
17. Demoly P, Bousquet J (2006) The relation between asthma and allergic rhinitis. Lancet 368:711-713 (Pubitemid 44279038)
18. Desreumaux, P, Capron M (1996) Eosinophils in allergic reactions. Curr Opin Immunol 8: 790-795 (Pubitemid 27007645)
19. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S (2006) Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjuncivitis. J Allergy Clin Immunol 117:802-809
20. Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S, Stoecklinger A, Kneidinger M, Valent P, Campana R, Thalhamer J, Popow-Kraupp T, Valenta R (2009) A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 182:6298-6306
21. Edlmayr J, Niespodziana K, Popow-Kraupp T, Krzyzanek V, Focke-Tejkl M, Blaas D, Grote M, Valenta R (2011) Antibodies induced with recombinant VP1 from Human rhinovirus exhibit cross-neutralization. Eur Respir J 37:44-52
22. Fang KS, Vitale M, Fehlner P, King TP (1988) cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5. Proc Natl Acad Sci USA 85:895-899 (Pubitemid 18073934)
23. Feinberg SM (1940) Oral pollen therapy in ragweed pollinosis. J Am Med Assoc 115:231
24. Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R (2001) Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. Faseb J 15:2042-2044
25. Focke M, Linhart B, Hartl A, Wiedermann U, Sperr WR, Valent P, Thalhamer J, Kraft D, Valenta R (2004) Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 34:1525-1533 (Pubitemid 39389328)
26. Focke M, Marth K, Flicker S, Valenta R (2008) Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 38:1400-1408 (Pubitemid 352019672)
27. Focke M, Marth K, Valenta R (2009) Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest 39:429-436
28. Focke M, Swoboda I, Marth K, Valenta R (2010) Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 40:385-397
29. Frankland AW, Augustin R (1954) Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 266:1055-1057
30. Frankland AW, Hughes WH, Gorrill RH (1955) Autogenous bacterial vaccines in treatment of asthma. Br Med J 2:941-944
31. Freeman J (1914) Vaccination against hay fever; report of results during the last three years Lancet 1:1178
32. Garn H, Renz H (2007) Epidemiological and immunological evidence for the hygiene hypothesis. Immunobiology 212:441-452 (Pubitemid 46825255)
33. Greve JM, Davis G, Meyer AM (1989) The major human rhinovirus receptor is ICAM-1. Cell 56: 839-847 (Pubitemid 19082519)
34. Haselden BM, Kay AB, Larche M (1999) Immunoglobulin E-independent major histocompat-ibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 189:1885-1894 (Pubitemid 29295887)
35. Helander E (1959) Bacterial vaccines in the treatment of bronchial asthma. Acta Allergy 13:47
36. Henderson LL, Larson JB, Gleich GJ (1975) Maximal rise in IgE antibody following ragweed pollination season. J Allergy Clin Immunol 55:10-15
37. Holgate ST (2006) Rhinoviruses in the pathogenesis of asthma: the bronchial epithelium as a major disease target. J Allergy Clin Immunol 118:587-590 (Pubitemid 44301406)
38. Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, Hsieh KH (1996) Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 2:540-544
39. Ishizaka K, Ishizaka T (1967) Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 99:1187-1198
40. Johansson SG, Bennich H (1967) Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 13:381-384
41. Johnstone DE (1957) Study of the value of bacterial vaccines in the treatment of bronchial asthma associated with respiratory infections. Am J Dis Child 94:1
42. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O (2005) Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116:608-613 (Pubitemid 41267135)
43. King TP, Norman PS (1962) Isolation studies of allergens from ragweed pollen. Biochemistry 1:709
44. Klimek L, Bachert C, Doemer C, Meyer H, Narkus A (2005) Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious. Allergy Clin Immunol Int (Suppl 1):15
45. Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U (1999) Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 103:1173-1179 (Pubitemid 29343086)
46. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF (2006) Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117:1470-1476 (Pubitemid 43795737)
47. Laetsch C, Wuthrich B (1973) Peroral desensitization of inhalation allergies in childhood: treatment results. Schweiz Med Wochenschr 103:342-347
48. Larche M, Robinson DS, Kay AB (2003) The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 111:450-463, quiz 464 (Pubitemid 36337859)
49. Larche M, Akdis CA, Valenta R (2006) Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6:761-771 (Pubitemid 44453462)
50. Lee WY, Sehon AH (1978) Suppression of reaginic antibodies with modified allergens. I. Reduction in allergenicity of protein allergens by conjugation to polyethylene glycol. Int Arch Allergy Appl Immunol 56:159-170 (Pubitemid 8261232)
51. Lichtenstein LM, Holtzman NA, Burnett LS (1968) A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 101:317-324
52. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, Valenta R (2002) Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. Faseb J 16:1301-1303
53. Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, Krauth MT, Valent P, Horak F, Wiedermann U, Thalhamer J, Ebner C, Kraft D, Valenta R (2005) A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 115:1010-1016 (Pubitemid 40616216)
54. Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R (2008) A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol chem 389:925-933
55. Loveless MH (1940) Immunological studies of pollenosis. IV. The presence of two antibodies related to the same pollen antigen in the serum of treated hay fever patients. J Immunol 38:20-50
56. Lowell FC, Franklin W (1965) A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. N Engl J Med 273:675-679
57. Lynch NR, Thomas WR, Chua Y, Garcia N, Di Prisco MC, Lopez R (1994) In vivo biological activity of recombinant Der p II allergen of house-dust mite. Int Arch Allergy Immunol 105:70-74 (Pubitemid 24281004)
58. MacKenzie GM (1922) Desensitzation of hay fever patients by specific local application. J Am Med Assoc 78:787
59. Malley A, Perlman F (1969) Induction of both reaginic and blocking antibodies with a low molecular weight fraction of timothy pollen extract. J Allergy 43:59-64
60. Marsh DG, Lichtenstein LM, Campbell DH (1970) Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 18:705-722
61. Mellerup MT, Hahn GW, Poulsen LK, Malling H (2000) Safety of allergen specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 30:1423-1429
62. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109:251-256 (Pubitemid 34158289)
63. Morrey CB (1913) Vaccination with mixed cultures from the nose in hay fever. J Am Med Assoc 61:1806
64. Mosbech H, Dreborg S, Madsen F, Ohlsson H, Stahl Skov P, Taudorf E, Weeke B (1987) High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy 42:451-455 (Pubitemid 17144412)
65. Moser M, Crameri R, Brust E, Suter M, Menz G (1994) Diagnostic value of recombinant Aspergillus fumigatus allergen I/a for skin testing and serology. J Allergy Clin Immunol 93:1-11
66. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist V, Gafvelin G, Gronlund H, Purohit A, Suck R, Fiebig H,Cromwell O, Pauli G, Van Hage-Hamsten M, Valenta R (2004) Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101(Suppl 2):14677-14682 (Pubitemid 39346742)
67. Niederberger V, Niggemann B, Kraft D, Spitzauer S, Valenta R (2002) Evolution of IgM, IgE and IgG(1-4)antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms. Eur J Immunol 32:576-584 (Pubitemid 34173348)
68. Niederberger V, Ring J, Rakoski J, Jager S, Spitzauer S, Valent P, Horak F, Kundi M, Valenta R (2007) Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol 142:133-144 (Pubitemid 46095925)
69. Niemi M, Jylhä S, Laukkanen ML, Söderlund H, Mäkinen-Kijunen S, Kallio JM, Hakulinen N, Haahtela T, Takkinen K, Rouvinen J (2007) Molecular interactions between a recombinant IgE antibody and the beta-lactoglobulin allergen. Structure 15:1413-1421 (Pubitemid 350051924)
70. Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, van Hage M, Grönlund H, Valenta R (2011) A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol [Epub ahead of print]
71. Noon L (1911) Prophylactic inoculation against hay fever. Lancet 1:1572-1573
72. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF (1996) Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 154:1623-1628 (Pubitemid 26424925)
73. Padavattan S, Flicker S, Schirmer T, Madritsch C, Randow S, Reese G, Vieths S, Lupinek C, Ebner C, Valenta R, Markovic-Housley Z (2009) J Immunol 1822141-1822151
74. Paronchi P, Macchia D, Piccini MP, Biswas P, Simonelli C, Maggi E, Ricci M, Ansari AA, Romagnani S (1991) Allergen-and bacterial amtigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad Sci USA 15:4538-4542 (Pubitemid 21914576)
75. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, Mothes N, Spitzauer S, Montagut A, Galvain S, Melac M, André C, Poulsen LK, Malling HJ (2008) Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 122(5):951-960
76. Peters SP, Ferguson G, Deniz Y, Reisner C (2006) Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 100:1139-1151 (Pubitemid 43793051)
77. Platts-Mills TA (2005) Asthma severity and prevalence: an ongoing interaction between exposure, hygiene, and lifestyle. PLoS Med 2:e34
78. Prausnitz C, Kuestner J (1921) Studien über die Ü berempfindlichkeit. Centralbe F Bakt 1 ABT Orig 86:160-168
79. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R, Weber B, Fiebig H, van Hage M, Pauli G, Valenta R, Cromwell O (2008) Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38:1514-1525
80. Radulovic S, Calderon MA, Wilson D, Durham S (2010) Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 12:CD002893
81. Rak S (2009) Clinical results with a hypoallergenic recombinant birch pollen allergen derivative. Presented at 27th Congr, EAACI 2009, Warsaw, June 6-10
82. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA (1996) Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 93:5141-5145 (Pubitemid 26162885)
83. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL (1980) Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 302:1213-1219 (Pubitemid 10112392)
84. Scadding GK, Brostoff J (1986) Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 16:483-491 (Pubitemid 16006675)
85. Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S (2009) Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 206:1941-1955
86. Schumann A, Fiedler M, Dahmen U, Grosse-Wilde H, Roggendorf, M, Lindemann M (2007) Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat 14:592-598 (Pubitemid 47075432)
87. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT (1993) Allergen immunotherapy decreases interleukin 4 production in CD+ T cells from allergic individuals. J Exp Med 1:2123-2130 (Pubitemid 23344869)
88. Sehon LZ, Mohapatra SS (1992) Induction of IgE antibodies in mice with recombinant grass pollen antigens. Immunology 76:158-163
89. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT (2004) Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostim-ulatory DNA. J Allergy Clin Immunol 113:1144-1151 (Pubitemid 38857998)
90. Siskind GW, Paul WE, Benacerraf B (1966) Studies on the effect of the carrier molecule on antihapten antibody synthesis. I. Effect of carrier on the nature of the antibody synthesized. J Exp Med 123:673-688
91. Stull A, Cooke RA, Tenant J (1933) The allergen content of protein extracts: Its determination and deterioration. J Allergy 4:455
92. Touart MD (1922) Hay fever; Desensitization by ingestion of pollen protein. NY Med J 116:199
93. Twaroch TE, Focke M, Civaj V, Weber M, Balic N, Mari A, Ferrara R, Quirce S, Spitzauer S, Swoboda I, Valenta R (2011) Carrier-bound, non-allergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol [Epub ahead of print]
94. Urbanek R, Burgelin KH, Kahle S, Kuhn W, Wahn U (1990) Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response. Eur J Pediatr 149:545-550 (Pubitemid 20184015)
95. Valenta R (2002) The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2:446-453 (Pubitemid 37328752)
96. Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, Hirschwehr R, Breitenbach M, Rumpold H, Scheiner O, Kraft D (1991) Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 88:889-894
97. Valenta R, Ball T, Focke M, Linhart M, Mothes N, Niederberger V, Spitzauer S, Swoboda I, Vrtala S, Westritsching K, Kraft D (2004) Immunotherapy of allergic disease. Adv Immunol 82:105-153 (Pubitemid 38213117)
98. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, Vrtala S (2010) From allergen genes to allergy vaccines. Annu Rev Immunol 28:211-241
99. Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, Niederberger V (2011) Recombinant allergens: what does the future hold? J Allergy Clin Immunol 127(4):860-864
100. van Neerven RJ, Knol EF, Ejrnaes A, Wurtzen PA (2006) IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 141:119-129 (Pubitemid 44413287)
101. Vercelli D (2006) Mechanisms of the hygiene hypothesis-molecular and otherwise. Curr Opin Immunol 18:733-737
102. Walker JW, Adkinson J (1917) Studies on staphylococcus pyogens aureus, albus and citreus and on Micrococcus tetragenous and M. catarrhalis. J Med Res 35:391
103. Wide L, Bennich H, Johansson SG (1967) Diagnosis of allergy by an in vitro test for allergen antibodies. Lancet 2:1105-1107
104. Wyman M (1872) Autumnal Catarrh. Hurd and Houghton, Cambridge
105. Yunginger JW, Gleich GJ (1973) Seasonal changes in serum and nasal IgE concentrations. J Allergy Clin Immunol 51:174-186
106. Zoss AR, Koch CA, RS Hirose (1937) Alum-ragweed precipitate: preperation and clinical investigation; preliminary report. J Allergy 8:329-335